**Faruqi & Faruqi, LLP Investigates Potential Securities Claims Against Telix Pharmaceuticals Limited**
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Investors are reminded of the January 9, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
With offices in New York, Pennsylvania, California, and Georgia, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors since its founding in 1995. For more information, please visit [www.faruqilaw.com](http://www.faruqilaw.com).
### Allegations Against Telix Pharmaceuticals
The complaint alleges that Telix Pharmaceuticals and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose critical information, including:
1. Materially overstating the progress Telix had made regarding prostate cancer therapeutic candidates;
2. Overstating the quality of Telix’s supply chain and partners;
3. Making statements about Telix’s business, operations, and prospects that were materially false, misleading, and/or lacked a reasonable basis at all relevant times.
When the true details became public, the lawsuit claims that investors suffered significant damages.
### Key Developments
– **July 22, 2025:** Telix Pharmaceuticals revealed that it received a subpoena from the U.S. Securities and Exchange Commission (SEC), seeking various documents and information primarily related to the Company’s disclosures regarding the development of its prostate cancer therapeutics candidates. Following this announcement, the price of Telix Pharmaceuticals American Depositary Shares (“ADSs”) dropped more than 13% over two trading sessions.
– **August 28, 2025:** Telix disclosed it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) concerning its Biologics License Application for TLX250-CDx. The FDA identified “deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package” and issued notices of deficiency (Form 483) to two third-party manufacturing and supply chain partners, requiring remediation prior to resubmission. In response, the price of Telix Pharmaceuticals ADSs fell more than 21% over two trading sessions.
### Lead Plaintiff Role and How to Participate
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who is also adequate and typical of class members. This lead plaintiff directs and oversees the litigation on behalf of the class.
Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice. Alternatively, investors may choose to do nothing and remain absent class members. Your ability to share in any recovery will not be affected by your decision to serve as lead plaintiff or not.
### Contact Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP encourages anyone with information regarding Telix Pharmaceuticals’ conduct to contact the firm. This includes whistleblowers, former employees, shareholders, and others.
**Attorney Advertising.** The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ([www.faruqilaw.com](http://www.faruqilaw.com)). Prior results do not guarantee or predict a similar outcome in any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated confidentially.
https://markets.businessinsider.com/news/stocks/shareholder-alert-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-telix-pharmaceuticals-1035564995
About the Author
